NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.

Published on Aug 27, 2020in International Journal of Radiation Oncology Biology Physics7.038
路 DOI :10.1016/J.IJROBP.2020.08.034
William A. Hall26
Estimated H-index: 26
(MCW: Medical College of Wisconsin),
Eric S. Paulson21
Estimated H-index: 21
(MCW: Medical College of Wisconsin)
+ 22 AuthorsColleen A. Lawton61
Estimated H-index: 61
(MCW: Medical College of Wisconsin)
Sources
Abstract
Purpose In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing nodal recurrence patterns. The objective of this study is to provide an updated prostate pelvic nodal consensus atlas. Methods and materials A literature review was performed abstracting data on nodal recurrence patterns. Data were presented to a panel of international experts, including radiation oncologists, radiologists, and urologists. After data review, participants contoured nodal CTVs on 3 cases: postoperative, intact node positive, and intact node negative. Radiation oncologist contours were analyzed qualitatively using count maps, which provided a visual assessment of controversial regions, and quantitatively analyzed using Sorensen-Dice similarity coefficients and Hausdorff distances compared with the 2009 RTOG atlas. Diagnostic radiologists generated a reference table outlining considerations for determining clinical node positivity. Results Eighteen radiation oncologists' contours (54 CTVs) were included. Two urologists' volumes were examined in a separate analysis. The mean CTV for the postoperative case was 302 cm3, intact node positive case was 409 cm3, and intact node negative case was 342 cm3. Compared with the original RTOG consensus, the mean Sorensen-Dice similarity coefficient for the postoperative case was 0.63 (standard deviation [SD] 0.13), the intact node positive case was 0.68 (SD 0.13), and the intact node negative case was 0.66 (SD 0.18). The mean Hausdorff distance (in cm) for the postoperative case was 0.24 (SD 0.13), the intact node positive case was 0.23 (SD 0.09), and intact node negative case was 0.33 (SD 0.24). Four regions of CTV controversy were identified, and consensus for each of these areas was reached. Conclusions Discordance with the 2009 RTOG consensus atlas was seen in a group of experienced NRG Oncology and international genitourinary radiation oncologists. To address areas of variability and account for new data, an updated NRG Oncology consensus contour atlas was developed.
馃摉 Papers frequently viewed together
20163.24PLOS ONE
18 Authors (David Pasquier, ..., Eric Lartigau)
References40
Newest
#1Ibrahim Abu-Gheida (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Tharakeswara K. Bathala (University of Texas MD Anderson Cancer Center)H-Index: 9
Last. Chad Tang (University of Texas MD Anderson Cancer Center)H-Index: 35
view all 15 authors...
Purpose Patients with prostate cancer presenting with advanced T stage, mainly T4, might have a unique pattern of nodal failure and disease involvement that is not typically covered when local therapy is offered. We attempted to identify common sites of nodal disease presentation and failure for patients presenting with cT4 prostate cancer. Methods and Materials All patients with treatment-naive cT4 prostate cancer were retrospectively identified. All patients were required to have a confirmed d...
Source
#1Michael S. Hofman (University of Melbourne)H-Index: 47
#2Nathan Lawrentschuk (University of Melbourne)H-Index: 58
Last. Ramdave ShakherH-Index: 4
view all 26 authors...
Summary Background Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management. Methods In this multicentre, two-arm, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conve...
Source
#1Julia Murray (ICR: Institute of Cancer Research)H-Index: 8
#2Sarah L. Gulliford (ICR: Institute of Cancer Research)H-Index: 24
Last. CHHiP InvestigatorsH-Index: 3
view all 19 authors...
Abstract Background and purpose The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms (DVHs) in patients treated with prostate radiotherapy, and to identify clinical and dosimetric parameters that predict the risk of ED post prostate radiotherapy. Materials and methods Penile bulb DVHs were generated for 276 patients treated within the randomised IGRT subst...
Source
#1Anna Wilkins (The Royal Marsden NHS Foundation Trust)H-Index: 11
#2O. Naismith (The Royal Marsden NHS Foundation Trust)H-Index: 12
Last. Sarah L. GullifordH-Index: 24
view all 7 authors...
Abstract Background The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based dose constraints were applied with arithmetic adjustment for the hypofractionated arms. This study aimed to derive anorectal dose constraints using prospectively-collected clinician-reported outcomes (CRO) and patient-reported outcomes (PRO) and to assess the ad...
Source
: Prostate cancer remains one of the top common cancers in terms of incidence and cancer-related deaths. Approximately 1/3rd cases develop biochemical recurrence during surveillance post-definite therapy. Multiple imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI) (including multiparametric prostate MRI), bone scan, and positron emission tomography (PET) using different tracers are being used for the characterization of the prostate cancer recurrence. CT and...
Source
Source
#1C. M. de Korne (LUMC: Leiden University Medical Center)H-Index: 1
#2Esther Wit (NKI-AVL: Netherlands Cancer Institute)H-Index: 13
Last. H.G. Van Der Poel (NKI-AVL: Netherlands Cancer Institute)H-Index: 25
view all 7 authors...
Purpose Diagnostic imaging modalities have moderate sensitivity for the identification of lymph node (LN) metastases in prostate cancer (PCa) patients. Mapping the lymphatic drainage from the prostate can help to identify the LNs directly draining from the tumour (sentinel nodes (SNs)); the LNs stated to have the highest chance of containing metastatic cancer cells. Although the lymphatic drainage may differ between segments within the prostate, the location of the primary tumour is not routinel...
Source
#1Krishan R. Jethwa (UR: University of Rochester)H-Index: 1
#2Christopher D. Hellekson (UR: University of Rochester)H-Index: 1
Last. Brian J. Davis (UR: University of Rochester)H-Index: 2
view all 18 authors...
Abstract Purpose To assess gastrointestinal (GI) and genitourinary (GU) adverse events (AEs) of 11C-choline-positron emission tomography (CholPET) guided lymph node (LN) radiation therapy (RT) in patients who experience biochemical failure after radical prostatectomy. Methods and Materials From 2013 to 2016, 107 patients experienced biochemical failure of prostate cancer, had CholPET-detected pelvic and/or paraortic LN recurrence, and were referred for RT. Patients received androgen suppression ...
Source
#1Aur茅lie De Bruycker (UGent: Ghent University)H-Index: 7
#2Elise De Bleser (Ghent University Hospital)H-Index: 6
Last. Piet Ost (UGent: Ghent University)H-Index: 44
view all 10 authors...
Abstract Background Patients with biochemical recurrence following primary prostate cancer (PCa) treatment often experience relapse in the lymph nodes (LNs). Both salvage LN dissection (sLND) and elective nodal radiotherapy (ENRT) are potential treatment options. Objective To describe anatomic patterns of nodal oligorecurrent PCa in relation to different surgical and radiotherapy templates. Design, setting, and participants Patients with biochemical recurrence following primary PCa treatment wer...
Source
#1James L. Mohler (Roswell Park Cancer Institute)H-Index: 73
#2Emmanuel S. Antonarakis (Johns Hopkins University)H-Index: 65
Last. Celestia S. Higano (Fred Hutchinson Cancer Research Center)H-Index: 88
view all 33 authors...
: The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal thera...
Source
Cited By19
Newest
#1David Pryor (Princess Alexandra Hospital)H-Index: 14
#2Jarad Martin (University of Newcastle)
Last. Michael O'Callaghan (Flinders Medical Centre)H-Index: 1
view all 14 authors...
Importance null Randomized clinical trials in prostate cancer have reported noninferior outcomes for hypofractionated radiation therapy (HRT) compared with conventional RT (CRT); however, uptake of HRT across jurisdictions is variable. null Objective null To evaluate the use of HRT vs CRT in men with nonmetastatic prostate cancer and compare patient-reported outcomes (PROs) at a population level. null Design, Setting, and Participants null Registry-based cohort study from the Australian and New ...
Source
#1Jennifer le Guevelou (Geneva College)
#2V茅rane Achard (Geneva College)H-Index: 6
Last. Thomas Zilli (Geneva College)H-Index: 22
view all 9 authors...
Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further recurrence. Positron emission tomography with computed tomography (PET/CT) using prostate cancer-targeting radiotracers has emerged in the last decade as a new generation imaging technique characteriz...
Source
#1Shaurav MaulikH-Index: 1
#2M. ArunsinghH-Index: 6
Last. Indranil MallickH-Index: 4
view all 5 authors...
Abstract null null Aims null There is a paucity of long-term data on outcomes of high-risk prostatic adenocarcinoma after moderately hypofractionated radiotherapy with elective nodal treatment and long-term androgen deprivation therapy (ADT). We report long-term control and toxicity outcomes and analyse the predictors of failure and toxicity. null null null Materials and methods null The records of 120 consecutive high-risk prostate cancer patients treated in a single institution between Februar...
Source
#1Michael Yan (Queen's University)H-Index: 4
Last. Fabio Y. Moraes (Queen's University)H-Index: 13
view all 9 authors...
External beam radiotherapy is an effective curative treatment option for localized prostate cancer, the most common cancer in men worldwide. However, conventionally fractionated courses of curative external beam radiotherapy are usually 8-9 weeks long, resulting in a substantial burden to patients and the health-care system. This problem is exacerbated in low-income and middle-income countries where health-care resources might be scarce and patient funds limited. Trials have shown a clinical equ...
Source
#1Ulrike Schick (French Institute of Health and Medical Research)H-Index: 24
#2I. LatorzeffH-Index: 8
Last. Paul SargosH-Index: 18
view all 3 authors...
Abstract null null Approximately thirty percent of patients experience biochemical recurrence after radical prostatectomy for prostate cancer. Early salvage radiotherapy has recently become a standard of care in this setting. The purpose of this review is first to summarize current knowledge in terms of dose to the prostate bed in light of the recent SAKK 09/10 randomized phase III trial results. The evidence on moderate hypofractionation will also be discussed whereas extreme hypofractionation ...
Source
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurren...
Source
#1Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
Last. Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
view all 13 authors...
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT trial established the role of elective whole pelvis radiotherapy in patients who have more than a 35% risk of lymph node invasion (known as the Roach formula). POP-RT stre...
Source
Source
#1F. Slevin (University of Leeds)H-Index: 4
#2Christopher M Thompson (Leeds Teaching Hospitals NHS Trust)
Last. Ann Henry (Leeds Teaching Hospitals NHS Trust)H-Index: 34
view all 6 authors...
Prostate cancer (PCa) may recur after primary treatment but no standard of care exists for patients with pelvic nodal relapse. Based on obervational data, Extended Nodal Irradiation (ENI) might be associated with fewer treatment failures than Stereotactic Ablative Radiotherapy (SABR) to the involved node(s) alone. Ultra hypofractionated ENI is yet to be evaluated in this setting, but it could provide a therapeutic advantage if PCa has a low 伪/尾 ratio in addition to patient convenience/resource b...
Source
#1Jonathan KhalifaH-Index: 10
#2St茅phane SupiotH-Index: 28
Last. Olivier RiouH-Index: 8
view all 20 authors...
Abstract null null Purpose null Curative radio-chemotherapy is recognized as a standard treatment option for muscle-invasive bladder cancer (MIBC). Nevertheless, the technical aspects for MIBC radiotherapy are heterogeneous with a lack of practical recommendations. null null null Methods and Materials null In 2018, a workshop identified the need for two cooperative groups to develop consistent, evidence-based guidelines for irradiation technique in the delivery of curative radiotherapy. Two radi...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.